The European Commission has informed India’s Alchem International and its Hong Kong subsidiary of its preliminary view “that they have breached EU antitrust rules by participating in a long-lasting cartel concerning an important pharmaceutical product”. If the EC ultimately concludes that there is sufficient evidence of an infringement, it can impose a fine of up to 10% of the company's worldwide turnover.